NeuroDerm CEO to Present at the 34th Annual J.P. Morgan  Healthcare Conference on January 14, 2016


REHOVOT, Israel, Jan. 04, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:00am PT in San Francisco.  Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.

To access the live webcast of the presentation, please visit ir.neuroderm.com/.  A replay will be available for one month following the presentation.

About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.

NeuroDerm Contact:
Oded S. Lieberman, PhD MBA, CEO
oded@neuroderm.com
Tel.: +972-8-946 2729
Cell: +1-617-517 6077

U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
dcarey@lazarpartners.com
+212-867-1762